BACKGROUND: Commercial sex venues (e.g., bathhouses) that cater to men who have sex with men (MSM) continue to function in most urban areas. These venues present a challenge to developing strategies to prevent the spread of the human immunodeficiency virus (HIV), but they also provide opportunities for interventions to reduce the risk and rate of disease transmission. Several cities in the United States have developed programs that offer HIV testing in these venues. Similar programs have not existed before in New York City. METHODS: A pilot HIV testing program was implemented at 2 New York City bathhouses. Testing included rapid HIV testing, the use of the serologic testing algorithm for recent HIV seroconversion, and pooled plasma HIV viral load to detect and date incident and acute HIV infections. In addition to HIV tests, behavioral and demographic data were collected from 493 presumed HIV-negative participants. RESULTS: The pilot program recruited MSM who were at high risk for HIV infection. Of the 493 men tested, 20 (4%) were found to be positive for HIV, and 8 (40%) of these 20 men demonstrated evidence of acute or recent HIV infection. The program tested men often not tested in more traditional medical settings. Significant disparities were demonstrated in the testing habits of MSM who reported having sex with women and had not disclosed same-sex activities to their caregivers. CONCLUSIONS: Bathhouse-based testing for HIV infection can be implemented in New York City and would include a population of MSM who are at high risk for HIV infection. Because of the high rate of recent HIV infection, expanded testing in these venues may be a good strategy to reduce the forward transmission of HIV in this highly sexually active population.
BACKGROUND: Commercial sex venues (e.g., bathhouses) that cater to men who have sex with men (MSM) continue to function in most urban areas. These venues present a challenge to developing strategies to prevent the spread of the human immunodeficiency virus (HIV), but they also provide opportunities for interventions to reduce the risk and rate of disease transmission. Several cities in the United States have developed programs that offer HIV testing in these venues. Similar programs have not existed before in New York City. METHODS: A pilot HIV testing program was implemented at 2 New York City bathhouses. Testing included rapid HIV testing, the use of the serologic testing algorithm for recent HIV seroconversion, and pooled plasma HIV viral load to detect and date incident and acute HIV infections. In addition to HIV tests, behavioral and demographic data were collected from 493 presumed HIV-negative participants. RESULTS: The pilot program recruited MSM who were at high risk for HIV infection. Of the 493 men tested, 20 (4%) were found to be positive for HIV, and 8 (40%) of these 20 men demonstrated evidence of acute or recent HIV infection. The program tested men often not tested in more traditional medical settings. Significant disparities were demonstrated in the testing habits of MSM who reported having sex with women and had not disclosed same-sex activities to their caregivers. CONCLUSIONS: Bathhouse-based testing for HIV infection can be implemented in New York City and would include a population of MSM who are at high risk for HIV infection. Because of the high rate of recent HIV infection, expanded testing in these venues may be a good strategy to reduce the forward transmission of HIV in this highly sexually active population.
Authors: Trista A Bingham; Gina M Secura; Stephanie K Behel; J Gordon Bunch; Paul A Simon; Duncan A MacKellar Journal: Sex Transm Dis Date: 2008-06 Impact factor: 2.830
Authors: Maria J Wawer; Ronald H Gray; Nelson K Sewankambo; David Serwadda; Xianbin Li; Oliver Laeyendecker; Noah Kiwanuka; Godfrey Kigozi; Mohammed Kiddugavu; Thomas Lutalo; Fred Nalugoda; Fred Wabwire-Mangen; Mary P Meehan; Thomas C Quinn Journal: J Infect Dis Date: 2005-03-30 Impact factor: 5.226
Authors: Chris A Van Beneden; Kerth O'Brien; Steve Modesitt; Suzanne Yusem; Alan Rose; David Fleming Journal: J Acquir Immune Defic Syndr Date: 2002-08-15 Impact factor: 3.731
Authors: R S Janssen; G A Satten; S L Stramer; B D Rawal; T R O'Brien; B J Weiblen; F M Hecht; N Jack; F R Cleghorn; J O Kahn; M A Chesney; M P Busch Journal: JAMA Date: 1998-07-01 Impact factor: 56.272
Authors: Frangiscos Sifakis; John B Hylton; Colin Flynn; Liza Solomon; Duncan A Mackellar; Linda A Valleroy; David D Celentano Journal: J Acquir Immune Defic Syndr Date: 2007-11-01 Impact factor: 3.731
Authors: Yvette Calderon; Ethan Cowan; John Y Rhee; Christopher Brusalis; Jason Leider Journal: AIDS Patient Care STDS Date: 2013-07-24 Impact factor: 5.078
Authors: Todd M Solomon; Perry N Halkitis; Robert M Moeller; Daniel E Siconolfi; Mathew V Kiang; Staci C Barton Journal: J Urban Health Date: 2011-12 Impact factor: 3.671
Authors: Kenneth H Mayer; Linda-Gail Bekker; Ron Stall; Andrew E Grulich; Grant Colfax; Javier R Lama Journal: Lancet Date: 2012-07-20 Impact factor: 79.321
Authors: Richard Silvera; Dylan Stein; Richard Hutt; Robert Hagerty; Demetre Daskalakis; Fred Valentine; Michael Marmor Journal: Open AIDS J Date: 2010-03-05